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Abstract
Background: The expression of the key iron regulatory 
hormone hepcidin is regulated by iron availability, inflam-
mation, hormones, hypoxia, and anaemia. Increased 
serum concentrations of hepcidin have recently been 
linked to atherosclerosis. We studied demographic, hae-
matologic, biochemical, and dietary correlates of serum 
hepcidin levels and its associations with incident cardio-
vascular disease and with carotid atherosclerosis.
Methods: Serum hepcidin concentrations were measured 
by tandem mass spectrometry in samples taken in 2000 
from 675 infection-free participants of the prospective 
population-based Bruneck study (age, mean±standard 
deviation, 66.0±10.2; 48.1% male). Blood parameters 
were measured by standard methods. Dietary intakes of 
iron and alcohol were surveyed with a food frequency 
questionnaire. Carotid atherosclerosis (365 cases) was 
assessed by ultrasound and subjects were observed for 
incident stroke, myocardial infarction, or sudden cardiac 
death (91 events) until 2010.
Results: Median (interquartile range) hepcidin levels 
were 2.27  nM (0.86, 4.15). Most hepcidin correlates were 
in line with hepcidin as an indicator of iron stores. Inde-
pendently of ferritin, hepcidin was related directly to 
physical activity (p = 0.024) and fibrinogen (p < 0.0001), 
and inversely to alcohol intake (p = 0.006), haemoglobin 
(p = 0.027), and γ-glutamyltransferase (p < 0.0001). Hepci-
din and hepcidin-to-ferritin ratio were not associated with 
prevalent carotid atherosclerosis (p = 0.43 and p = 0.79) or 
with incident cardiovascular disease (p = 0.62 and p = 0.33).
Conclusions: In this random sample of the general com-
munity, fibrinogen and γ-glutamyltransferase were the 
most significant hepcidin correlates independent of iron 
stores, and hepcidin was related to neither atherosclerosis 
nor cardiovascular disease.
Keywords: atherosclerosis; biomarkers; cardiovascular 
disease; hepcidin; iron metabolism.
Introduction
The liver-derived peptide hormone hepcidin is the 
master regulator of systemic iron homeostasis [1, 2]. 
Hepcidin expression is induced mainly in hepatocytes 
by iron loading, inflammatory signals, and endoplas-
mic reticulum stress whereas iron deficiency, hypoxia, 
anaemia, and several hormones reduce the formation of 
this peptide [1–7]. Hepcidin acts upon binding to the only 
known cellular iron export protein ferroportin, result-
ing in its internalisation, degradation and thus blockage 
of cellular iron egress [8]. As a consequence, hepcidin 
reduces duodenal iron absorption and iron release from 
hepatocytes and macrophages, thereby lowering sys-
temic iron levels and shifting iron from plasma to iron 
stores [2, 9].
Iron loading has been associated with an increased 
risk of atherosclerosis [10–12], and thus recent studies 
have evaluated a potential association of hepcidin with 
atherosclerosis and the putative utility of hepcidin 
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as a diagnostic or predictive marker in cardiovascular 
disease (CVD) [10, 13–16]. Hepcidin may predispose to 
atherosclerotic lesions and CVD by enhancing iron 
retention in plaque macrophages, thereby increasing 
iron catalysed oxidative stress and lipid oxidation, and 
promoting foam cell formation and plaque instability 
[10], which is further aggravated by hepcidin-medi-
ated inhibition of macrophage cholesterol efflux [13]. 
However, the cause effective roles of iron and hepcidin 
for the pathogenesis of atherosclerosis are still debated 
[11, 12, 16]. Experimental studies revealed conflicting 
results [13–15], and epidemiologic reports have mostly, 
but not exclusively [17], been restricted to selected 
patient populations [18–20].
This work aimed to comprehensively analyse the 
associations between hepcidin serum concentration and 
its correlates and to scrutinise the associations of hep-
cidin with carotid atherosclerosis and, for the first time, 
with its clinical sequels stroke, myocardial infarction and 
sudden cardiac death.
Materials and methods
An unabridged description of the study population and materi-
als and methods is available in the online-only Supplemental 
Data that accompanies the article at http://www.degruyter.com/
view/j/cclm.2016.54.issue-1/cclm-2015-0068/cclm-2015-0068.
xml?format=INT
Study population and data collection
The Bruneck Study is a prospective, population-based survey on the 
epidemiology and pathogenesis of atherosclerosis and CVD [21–23]. 
At baseline in 1990 the study population comprised an age- and sex-
stratified random sample of all inhabitants of Bruneck (125 men and 
125 women from each of the fifth through eighth decades of age, all 
of Western European descent; 93.4% participated). In 2000, 702 sub-
jects participated in the second quinquennial re-examination and 
serum samples for hepcidin measurement were available in 694 indi-
viduals. During follow-up from 2000 to 2010, detailed information 
about fatal and non-fatal new-onset CVD was carefully collected for 
all of these 694 subjects (follow-up rate, 100%). The study protocol 
was approved by the Ethics Committees of Bolzano and Verona and 
conforms to the Declaration of Helsinki. All study subjects provided 
written informed consent. Risk factors were assessed by means of 
validated standard procedures as described previously [21–24]. Blood 
samples were drawn in the morning between 7 and 9 AM after an 
overnight fast and 12 h of abstinence from smoking. In subjects with 
acute infection, blood sampling was delayed for at least 6 weeks, i.e. 
until at least 4–5 weeks after recovery from the respective infectious 
disease. Serum samples were divided into aliquots and immediately 
stored at −80 °C.
Hepcidin measurement
Hepcidin was quantified by tandem mass spectrometry using an 
adaptation of a published method [25] as detailed in the Supplemen-
tal Data.
Definition of clinical variables
Study participants underwent an extensive examination and com-
pleted a standardised questionnaire on medical history and lifestyle 
factors. Body mass index (BMI) was calculated as weight in kilo-
grams over height in meters squared. Total and high-density lipopro-
tein cholesterol were measured by standard procedures. Glomerular 
filtration rate was estimated based on serum creatinine according to 
the Modification of Diet in Renal Disease (MDRD) formula. Transfer-
rin saturation was derived from iron and transferrin concentrations, 
which were measured directly. Ferritin index was calculated as solu-
ble transferrin receptor (mg/L) divided by log10 ferritin (μg/L).
Anaemia was defined as haemoglobin  < 120 g/L in women 
and  < 130 g/L in men. Aetiologies of anaemia were classified accord-
ing to common criteria as detailed in the Supplemental Data.
Ascertainment of physical activity and of dietary intakes
We ascertained physical activity by the Baecke questionnaire, rated 
activity intensities according to the compendium of physical activi-
ties [26], and calculated average metabolic equivalent hours per week 
to quantify long-term physical activity. We assessed food intakes by 
a standardised dietician-supervised food-frequency questionnaire 
(FFQ).
Definition of atherosclerosis
Carotid artery ultrasound scans were recorded in 2000 for all sub-
jects in a supine position using a duplex ultrasound system with a 
10-MHz transducer [21, 27, 28]. Four segments of the right and left 
carotid artery were examined in multiple planes: proximal common 
carotid artery (15–30 mm proximal to the carotid bulb), distal com-
mon carotid artery ( < 15 mm proximal to the carotid bulb), proximal 
internal carotid artery (carotid bulb and the initial 10 mm of the ves-
sel), distal internal carotid artery ( > 10 mm above the flow divider). A 
plaque was defined as an echo structure protruding into the lumen 
with focal broadening of the vessel wall of at least 0.5 mm relative to 
adjacent segments.
Definition of the clinical endpoint
The composite CVD endpoint comprised incident ischaemic stroke, 
fatal and non-fatal myocardial infarction, and sudden cardiac death 
(n = 91). Presence of myocardial infarction was assessed by World 
Health Organization criteria (definite disease status) [29] while stroke 
was classified according to the criteria of the National Survey of 
Stroke [30].
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Statistical analysis
Data are presented as mean±standard deviation, median (first quar-
tile, third quartile), or count (percentage). p-Values were calculated 
by t-test, Wilcoxon-Mann-Whitney test, χ2-test or Fisher’s exact test 
as appropriate. The non-linear dependency of hepcidin concentra-
tion on age is shown using smooth 0.10, 0.25, 0.50, 0.75, and 0.90 
quantiles fitted by quantile regression [31].
Associations between hepcidin and other variables were exam-
ined by ordinary least squares regression. The dependent variable 
hepcidin and the independent variables ferritin, fibrinogen, hs-CRP, 
alanine aminotransferase, and γ-glutamyltransferase (γ-GT) were 
log2-transformed towards normality for these inferential analyses, 
and regression coefficients were back-transformed.
Associations of hepcidin and derived variables with atheroscle-
rosis were studied using logistic regression, and associations with 
CVD using Cox regression. The proportional hazards assumption was 
tested by computing the correlation between Schoenfeld residuals 
and follow-up time and was not refuted. These results are presented 
with adjustment for age, sex, C-reactive protein, anaemia, and the 
Framingham risk score variables age, sex, diabetes mellitus, current 
smoking, systolic blood pressure, and total and high-density lipopro-
tein cholesterol, which were summarised utilising full-cohort disease 
risk scores. P for trend was obtained by using hepcidin, hepcidin-to-
ferritin ratio, or hepcidin-to-transferrin saturation ratio as log-trans-
formed continuous predictor.
We used bootstrap aggregated backwards stepwise linear 
regression (1000 repetitions) based on Bayesian Information Crite-
rion minimisation to identify independent predictors of hepcidin 
concentration from those univariably significant in Table 2 in addi-
tion to age and sex.
More detail on statistical methods employed is given in the 
 Supplemental Data. An α level of 0.05 is used throughout and all 
p-values are two-sided. Analyses were conducted with R 3.1.0.
Results
Hepcidin could be measured in 675 of 694 participat-
ing subjects (97.3%), whose baseline characteristics 
are shown in Table 1. Levels and distribution of serum 
hepcidin concentration by age and sex are shown in 
Figure 1. In women, of which 95.7% had undergone meno-
pause, hepcidin levels on average increased by 15% per 
year from ages 50 to 60 (95% confidence interval, 5–25) 
and decreased by 3% (1–5) per year from ages 60 to 90. 
Average hepcidin levels in men did not change with age 
(p = 0.32) and were approximately 51% (23–84) higher than 
in women independently of age. Conditional on serum fer-
ritin men had 27% (14–38) lower average hepcidin levels. 
The relationship between hepcidin and ferritin in subjects 
with anaemia is shown in Figure 2. Compared to a median 
hepcidin concentration of 2.30 nmol/L (6.42 μg/L) in sub-
jects without anaemia (n = 651), median hepcidin con-
centrations in anaemic subjects by aetiology of anaemia 
were as follows: iron deficiency anaemia, 0.10 nmol/L 
(0.28 μg/L; n = 9); vitamin B12 or folate deficiency anaemia, 
4.31 nmol/L (12.0 μg/L; n = 3); anaemia of inflammation, 
3.88 nmol/L (10.8 μg/L; n = 3); anaemia of multiple aetiolo-
gies, 2.20 nmol/L (6.1 μg/L; n = 3).
Results on the relationships between hepcidin and 
iron, haematologic, inflammatory, and dietary variables 
in all study subjects and by sex are given in Table 2, and 
conditional on body iron stores assessed as ferritin in 
Table 3. Associations of hepcidin with iron parameters 
were generally highly significant (most p-values  < 0.001) 
and similar between sexes.
There were direct relationships of hepcidin with 
hs-CRP and with fibrinogen, but only that with fibrinogen 
was robust to adjustment for ferritin. We also examined 
the simultaneous associations of these inflammation 
markers with hepcidin upon adjustment for age, sex, 
and body mass index. Fibrinogen (p = 0.008) but not CRP 
(p = 0.24) was independently and significantly associated 
with circulating hepcidin.
γ-GT was highly significantly negatively related to 
hepcidin under adjustment for ferritin but not without 
such adjustment. Other kidney and liver parameters dis-
played non- or only weakly significant associations with 
hepcidin, which were poorly consistent under varying 
multivariable adjustment and between sexes.
Dietary intakes of alcohol showed marked sex differ-
ences in their association with hepcidin concentration. 
In women, alcohol intake was negatively associated with 
hepcidin levels even after ferritin adjustment, whereas a 
positive association between these two variables became 
evident in men, and this association ceased with adjust-
ment for ferritin.
Statistically selected independent predictors of hepci-
din concentration are presented in Table 4. There were no 
interactions by sex and they are therefore only presented 
in the sexes combined.
We then studied the associations of hepcidin, of 
hepcidin-to-ferritin ratio, and of hepcidin-to-TfS ratio 
levels with the prevalence of ultrasound determined 
carotid atherosclerosis (Online Table 1). We found no 
significant associations between any of these variables 
and the presence of carotid plaque in men or women. 
For sensitivity purposes we also examined effects in sub 
groups of blood donors and non-donors, alcohol drink-
ers ( > 1 g/day) and non-drinkers, subjects with increased 
( > 28.6 nmol/L,  > 3  mg/L) and with undetectable or low 
CRP (  ≤  28.6 nmol/L), non-anaemic subjects, subjects not 
taking statins, and subjects without prior CVD, which 
yielded no significant results. We then evaluated a pos-
sible association between the same variables and the 
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Table 1: Baseline characteristics of the study population. 
  All subjects  Men  Women  pSex difference
No. of subjects   675  325  350 
 Age, years   66.0±10.2  65.3±10.0  66.6±10.4  NS
Demographic and lifestyle variables
 Body mass index, kg/m2   25.4±4.0  25.4±3.5  25.5±4.5  NS
 Body mass index  > 30 kg/m2, n (%)   88 (13.3)  33 (10.4)  55 (15.9)  0.048
 Physical activity, MET-h/week   50.8±39.4  58.3±42.7  43.7±34.7   < 0.001
 Blood donation, n (%)   112 (16.7)  94 (29.3)  18 (5.2)   < 0.001
 Hormone replacement therapy, n (%)       71 (20.3) 
 Postmenopausal, n (%)       331 (95.7) 
 Prior CVD, n (%)   44 (6.5)  27 (8.3)  17 (4.9)  NS
Iron variables
 Hepcidin, nmol/L   2.27 (0.86, 4.15)  2.54 (1.13, 4.85)  1.98 (0.62, 3.72)   < 0.001
 Ferritin, pmol/L   181.8 (96.6, 329.2)  266.5 (135.9, 465.4)  133.0 (77.1, 222.2)   < 0.001
 Hepcidin-to-ferritin ratio, mol/mol   11.0 (5.5, 18.6)  9.3 (4.5, 14.6)  13.6 (6.6, 21.2)   < 0.001
 Iron, μmol/L   18.7±6.5  19.7±7.0  17.7±5.8   < 0.001
 Serum transferrin, μmol/L   27.8±4.6  27.3±4.7  28.2±4.5  0.009
 Transferrin saturation, %   31.7 (25.1, 40.6)  32.8 (26.6, 43.8)  30.8 (24.3, 37.9)   < 0.001
 Hepcidin-to-TfS ratio, pmol/L/%   65.4 (92.7)  73.3 (98.3)  61.5 (88.5)  0.007
 Soluble transferrin receptor, mg/L   1.30 (1.16, 1.48)  1.26 (1.13, 1.43)  1.33 (1.18, 1.53)   < 0.001
 Ferritin index   0.69 (0.57, 0.84)  0.62 (0.51, 0.75)  0.76 (0.63, 0.94)   < 0.001
Red blood cell variables
 Haemoglobin, g/L   144.3±12.1  150.7±11.0  138.3±9.8   < 0.001
 Haematocrit, %   42.4±3.5  44.2±3.2  40.7±2.9   < 0.001
 Erythrocyte count,  × 1012/L   4.60±0.42  4.75±0.43  4.46±0.36   < 0.001
 MCV, fL   92.2±5.3  93.2±5.7  91.2±4.8   < 0.001
 MCH, pg/cell   31.4±1.9  31.8±2.1  31.0±1.7   < 0.001
 MCHC, g/L   341±5  341±6  340±5  0.001
 Red cell distribution width, %   13.0 (12.6, 13.5)  13.0 (12.6, 13.5)  13.0 (12.6, 13.5)  NS
 Anaemiaa, n (%)   24 (3.6)  12 (3.7)  12 (3.4)  NS
Inflammation markers
 Fibrinogen, g/L   2.89±0.59  2.81±0.65  2.97±0.54   < 0.001
 hs-CRP, nmol/L   17.3 (8.8, 38.3)  16.3 (8.0, 36.3)  18.6 (9.3, 39.7)  NS
 hs-CRP  > 28.6 nmol/L, n (%)   222 (32.9)  97 (29.8)  125 (35.7)  NS
Liver and kidney parameters
 eGFR-MDRD, mL/min/1.73 m2   81.9±14.6  86.5±15.3  77.6±12.4   < 0.001
 eGFR-MDRD  < 60 mL/min/1.73 m2, n (%)   45 (6.7)  18 (5.5)  27 (7.7)  NS
 Alanine aminotransferase, μkat/L   0.35 (0.28, 0.48)  0.40 (0.30, 0.57)  0.33 (0.27, 0.42)   < 0.001
 Alanine aminotransferase  > 0.83 μkat/L, n (%)  45 (6.7)  32 (9.8)  13 (3.7)  0.002
 γ-Glutamyltransferase, μkat/L   0.42 (0.27, 0.72)  0.52 (0.35, 0.90)  0.33 (0.23, 0.48)   < 0.001
Dietary variables
 Iron intake, mg/day   13.7 (12.3, 15.3)  13.2 (11.9, 14.6)  14.2 (12.7, 16.4)   < 0.001
 Haeme iron intake, mg/day   0.80 (0.58, 1.08)  0.88 (0.62, 1.17)  0.76 (0.56, 0.98)   < 0.001
 Non-haeme iron intake, mg/day   12.7 (11.4, 14.3)  12.3 (10.8, 13.6)  13.2 (12.0, 14.9)   < 0.001
 Intake of iron supplements, n (%)   15 (2.2)  1 (0.3)  14 (4.0)  0.001
 Alcohol intake, g/day   13.6 (4.4, 30.7)  28.7 (11.6, 51.9)  8.0 (2.4, 15.3)   < 0.001
 Alcohol intake  > 1 g/day, n (%)   504 (75.1)  301 (92.9)  203 (58.5)   < 0.001
Values are given as mean±standard deviation, median (first quartile, third quartile), or count (percentage). CVD, cardiovascular disease; 
eGFR-MDRD, glomerular filtration rate estimated by the Modification of Diet in Renal Disease formula; hs-CRP, high-sensitivity C-reactive 
protein; MET-h/week, metabolic equivalent hours per week; MCH, mean cell haemoglobin; MCHC, mean corpuscular haemoglobin concen-
tration; MCV, mean corpuscular volume; NS, not significant. aAnaemia was defined as haemoglobin  < 120 g/L in women or  < 130 g/L in men. 
p-Values were calculated by t-test, Wilcoxon-Mann-Whitney test, χ2-test or Fisher’s exact test as appropriate. To convert serum hepcidin 
from nmol/L to ng/mL, multiply by 2.789. To convert ferritin from pmol/L to ng/mL, multiply by 0.445. To convert iron from μmol/L to μg/dL, 
multiply by 5.587. To convert serum transferrin from μmol/L to mg/dL, multiply by 8.130. To convert hs-CRP from nmol/L to mg/L, multiply 
by 1.908. To convert alanine aminotransferase or γ-glutamyltransferase from μkat/L to U/L, multiply by 59.880.
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emergence of composite CVD, defined as incident ischae-
mic stroke, fatal or non-fatal MI, or sudden cardiac death 
between 2000 and 2010 (Table 5). Although CVD events 
occurred in a total of 91 subjects, we did not detect any 
associations with CVD risk, irrespective of sex and also 
when examining the abovementioned sub groups.
Discussion
Herein we investigated hepcidin serum concentrations in 
a population-based study and examined its associations 
with laboratory and environmental factors, along with 
an analysis of its associations with atherosclerosis and 
Figure 1:  Serum concentrations of hepcidin by age and sex.
Upper panel: Points are jittered horizontally and points at the lower limit of detection also vertically to alleviate overplotting. Median, first 
and third quartiles, and 10th and 90th percentiles are shown as smooth quantiles. Lower panel: The same quantiles are given in decades of 
age (50–59, 60–69, 70–79, 80–89 years).
Aetiology
of anaemia
Figure 2: Joint distribution of hepcidin and ferritin in anaemic subjects by aetiology of anaemia and sex.
Symbols representing multiple aetiologies in the same subject are bordered by black rectangles. The grey shaded area marks iron defi-
ciency as defined by ferritin  < 67.4 pmol/L.
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with CVD. Of interest, hepcidin serum concentrations in 
this study were lower than those reported previously for 
subjects of similar age [17, 32–34], as was the ratio of hep-
cidin to serum ferritin [17, 35] (Figure 1 and Table 1). While 
this may be associated with the method of determination 
[34] or the fact that our subjects had no evidence of acute 
infection or active ongoing inflammatory disease, the 
most probable reason is that hepcidin levels are lowest in 
the morning and increase approximately two-fold during 
the day [36]. The median concentration we found with 
blood sampling between 7:00 AM and 9:00 AM (2.27 nM) 
closely matches that detected previously with sampling at 
8:30 AM (2.24 nM) [37].
With respect to the method we used ultra-high pres-
sure liquid chromatography coupled to triple quadru-
pole mass spectrometry [25], which combines a low limit 
of detection, a main advantage of immunoassays, with 
specificity for the bioactive hepcidin-25 isoform, a main 
advantage of mass spectrometry-based methods [34]. 
Importantly, we studied subjects that were randomly 
sampled from the general community, which in combina-
tion with the expected low impact of inflammation and 
Table 2: Relationships of hepcidin serum concentration with demographic, blood, and dietary variables (95% confidence intervals) under 
adjustment for age and sex. 
  All subjects  Men  Women  pInteraction
Demographic and lifestyle variables
 Body mass index, kg/m2   2.7 (0.1, 5.3)a  2.5 (−1.7, 6.9)  2.7 (−0.4, 6.0)  NS
 Physical activity, MET-h/week   0.19 (−0.08, 0.46)  0.41 (0.07, 0.75)a  −0.14 (−0.55, 0.28)  0.043
 Postmenopausal       391 (140, 908)c 
Iron variables
 Ferritin, pmol/L (log)   93 (82, 105)c  88 (72, 105)c  98 (82, 114)c  NS
 Iron, μmol/L   3.7 (2.1, 5.3)c  3.6 (1.5, 5.7)c  3.9 (1.4, 6.4)b  NS
 Serum transferrin, μmol/L   −8.3 (−10.2, 
−6.4)c
  −6.4 (−9.1, −3.6)c  −10.2 (−12.9, −7.5)c  0.046
 Transferrin saturation, %   2.7 (1.9, 3.4)c  2.3 (1.3, 3.3)c  3.2 (2.0, 4.4)c  NS
 Soluble transferrin receptor, mg/L   −48 (−62, −29)c  −36 (−58, −2)a  −60 (−75, −36)c  NS
 Ferritin index   −74 (−79, −68)c  −91 (−95, −84)c  −68 (−75, −60)c   < 0.001
Red blood cell variables
 Haemoglobin, g/L   0.66 (−0.33, 1.65)  −0.39 (−1.71, 0.95)  1.85 (0.42, 3.31)a  0.025
 MCV, fL   2.8 (0.9, 4.8)b  1.9 (−0.6, 4.5)  4.0 (1.0, 7.0)b  NS
 MCH, pg/cell   9.7 (4.1, 15.6)c  6.5 (−0.6, 14.2)  13.9 (5.2, 23.4)b  NS
 MCHC, g/L   3.1 (1.3, 5.2)c  2.3 (−0.4, 4.9)  4.3 (1.6, 7.2)b  NS
 Red cell distribution width, %   −14.1 (−22.1, 
−5.4)b
  −8.8 (−20.9, 5.1)  −18.4 (−28.4, −7.0)b  NS
 Anaemia   −27 (−58, 26)  27 (−41, 174)  −58 (−80, −9)a  0.047
Inflammation markers
 Fibrinogen, g/L (log)   119 (53, 213)c  70 (8, 168)a  212 (83, 434)c  NS
 hs-CRP, nmol/L (log)   14 (7, 22)c  12 (3, 23)a  17 (6, 28)b  NS
Liver and kidney parameters
 eGFR-MDRD  < 60 mL/min/1.73 m2   40 (−8, 114)  92 (0, 269)a  14 (−33, 94)  NS
 Alanine aminotransferase, μkat/L (log)   17 (1, 36)a  13 (−8, 39)  22 (−2, 51)  NS
 Alanine aminotransferase  > 0.83 μkat/L  37.4 (−8.5, 106.5)  8.9 (−33.0, 77.1)  134.3 (12.4, 388.6)a  NS
Dietary variables
 Haeme iron intake, mg/day   40 (9, 82)b  25 (−10, 74)  68 (11, 152)a  NS
 Intake of iron supplements   –48 (–74, 3)    −54 (−77, −6)a 
 Alcohol intake, g/day   0.43 (–0.00, 0.86)  0.71 (0.25, 1.18)b  −1.21 (−2.30, −0.10)a  0.002
Values represent the average percent change in hepcidin corresponding to a one unit increase in each row variable, except for vari-
ables that were analysed on the (log) scale, for which they represent the average percent change in hepcidin corresponding to a 100% 
increase in that variable. pInteraction is for tests of effect modification by sex. The column titled “All subjects” provides effect estimates in 
the sexes combined under adjustment for sex. No significant relationships were found for: Body mass index  > 30 kg/m2, blood dona-
tion, hormone replacement therapy (considered only in women), haematocrit, erythrocyte count, hs-CRP  > 28.6 nmol/L, eGFR-MDRD, 
γ-glutamyltransferase, iron intake, non-haeme iron intake, alcohol intake  > 1 g/day. eGFR-MDRD, glomerular filtration rate estimated by 
the Modification of Diet in Renal Disease formula; hs-CRP, high-sensitivity C-reactive protein; MET-h/week, metabolic equivalent hours per 
week; MCH, mean cell haemoglobin; MCHC, mean corpuscular haemoglobin concentration; MCV, mean corpuscular volume; NS, not signifi-
cant. ap < 0.05; bp < 0.01; cp < 0.001.
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the high-quality measurement of hepcidin argues that 
the values we registered are representative for the general 
population.
Hepcidin was strongly correlated with ferritin, as has 
been described previously [9, 32, 35, 38–41] (Table 2). In 
fact, a doubling of hepcidin concentration corresponded 
roughly to a doubling of ferritin concentration, likely 
because hepcidin and ferritin are physiologically simi-
larly affected by iron availability [38]. Factors associated 
with hepcidin independently of iron availability should 
thus emerge under adjustment for ferritin, such as was 
performed in Table 3. Safely employing this interpretation 
requires awareness that hepcidin but not ferritin affects 
iron availability as a key player in multiple feedback loops 
[1].
Along this line, men had higher hepcidin concentra-
tions, presumably due to their higher iron stores. However, 
conditional on ferritin, women had higher hepcidin 
Table 3: Relationships of hepcidin serum concentration with demographic, blood, and dietary variables (95% confidence intervals) under 
adjustment for age, sex and ferritin. 
  All subjects  Men  Women  pInteraction
Demographic and lifestyle variables
 Physical activity, MET-h/week   0.24 (0.03, 0.44)a  0.20 (−0.06, 0.46)  0.29 (−0.03, 0.61)  NS
 Blood donation   8.9 (−12.8, 35.9)  −2.3 (−23.7, 25.1)  67.1 (2.7, 171.9)a  NS
Red blood cell variables
 Haemoglobin, g/L   −0.86 (−1.62, −0.10)a  −1.32 (−2.33, 
−0.30)a
  −0.33 (−1.43, 0.78)  NS
 Haematocrit, %   −2.8 (−5.3, −0.2)a  −4.0 (−7.4, −0.5)a  −1.3 (−5.0, 2.5)  NS
Inflammation markers
 Fibrinogen, g/L (log)   73 (32, 128)c  69 (19, 140)b  80 (19, 173)b  NS
Liver and kidney parameters
 Alanine aminotransferase, μkat/L (log)   −10.9 (−20.9, 0.4)  −19.8 (−31.7, 
−5.7)b
  −0.1 (−15.5, 18.2)  NS
 Alanine aminotransferase  > 0.83 μkat/L  −23 (−44, 6)  −40 (−59, −12)b  36 (−23, 140)  0.025
 γ-Glutamyltransferase, μkat/L (log)   −15 (−22, −8)c  −18 (−27, −8)c  −13 (−22, −3)a  NS
Dietary variables
 Alcohol intake, g/day   −0.38 (−0.71, −0.04)a  −0.20 (−0.56, 0.17)  −1.37 (−2.21, −0.52)b  0.013
 Alcohol intake  > 1 g/day   −24 (−37, −8)b  −24 (−51, 17)  −24 (−38, −5)a  NS
Values represent the average percent change in hepcidin corresponding to a one unit increase in each row variable, except for variables 
that were analysed on the (log) scale, for which they represent the average percent change in hepcidin corresponding to a 100% increase 
in that variable. pInteraction is for tests of effect modification by sex. The column titled “All subjects” provides effect estimates in the sexes 
combined under additional adjustment for sex. No significant relationships were found for: Body mass index, body mass index  > 30 kg/m2, 
hormone replacement therapy or postmenopausal state (considered only in women), iron, serum transferrin, transferrin saturation, soluble 
transferrin receptor, ferritin index, erythrocyte count, MCV, MCH, MCHC, red cell distribution width, anaemia, hs-CRP, hs-CRP  > 28.6 nmol/L, 
eGFR-MDRD, eGFR-MDRD  < 60 mL/min/1.73 m2, iron intake, haeme iron intake, non-haeme iron intake, intake of iron supplements. eGFR-
MDRD, glomerular filtration rate estimated by the Modification of Diet in Renal Disease formula; hs-CRP, high-sensitivity C-reactive protein; 
MET-h/week, metabolic equivalent hours per week; MCH, mean cell haemoglobin; MCHC, mean corpuscular haemoglobin concentration; 
MCV, mean corpuscular volume; NS, not significant; ap < 0.05; bp < 0.01; cp < 0.001.
Table 4: Simultaneous correlates of serum hepcidin concentration. 
Variable   Effect (95% CI)  p-Value  t-Value  Partial R2 (%)
Ferritin, μg/L (log)   87.63 (76.25, 99.75)   < 0.001  19.75  32.2
Fibrinogen, g/L (log)   100.50 (51.83, 164.78)   < 0.001  4.91  2.0
γ-Glutamyltransferase, μkat/L (log)  −16.30 (−22.56, −9.53)   < 0.001  −4.50  1.7
Age, years   −1.18 (−1.95, −0.42)  0.003  −3.02  0.8
Transferrin saturation, %   0.80 (0.16, 1.46)  0.015  2.44  0.5
Values represent the average percent change in hepcidin corresponding to a one unit increase in each row variable, except for variables 
that were analysed on the (log) scale, for which they represent the average percent change in hepcidin corresponding to a 100% increase in 
that variable. Partial R2 represents the change in model R2 (percent variance explained) upon inclusion of one variable on top of the others.
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concentrations, which was also reflected in a higher hep-
cidin-to-ferritin ratio in women and has been described 
before [17, 35]. This observation may be linked to the effect 
of different hormones on hepcidin regulation [3, 4, 7], as 
few women in this study were premenopausal (4.3%).
All associations between hepcidin levels and iron 
parameters were highly significant without but non-sig-
nificant with adjustment for ferritin (Table 3). Given that 
hepcidin is regulated by circulating iron levels indepen-
dently of tissue iron stores [1, 2], it is unexpected that we, 
as others before [32, 35], found no respective independent 
association. This may reflect that metabolically available 
iron is rapidly incorporated into ferritin and a steady state 
between circulating ferritin, iron, and hepcidin develops.
The relationships of hepcidin with red blood cell 
indices were strongly affected by iron status, and iron 
deficiency was associated with low hepcidin levels and 
microcytic anaemia (Table 2). Following adjustment for 
ferritin, a negative association of haemoglobin with hepci-
din became evident, which tended to be more pronounced 
in men (Table 3). This picture is more consistent with 
anaemia of chronic disease or anaemia of inflammation, 
a normocytic anaemia in which hepcidin levels and fer-
ritin are normal to high [42]. Naturally, these are putative 
aetiologies; anaemia in the elderly is often of multifacto-
rial aetiology [43]. Given the low prevalence of definite 
anaemia as defined by haemoglobin cut-off ( < 120 g/L in 
women,  < 130 g/L in men) in our sample (Table 1), sub-
jects with low-normal haemoglobin levels may have con-
tributed significantly to these associations, which would 
be in line with the high prevalence of predominantly mild 
anaemia in the elderly [43].
Figure 2 provides a more detailed description of the 
aetiologies of definite anaemia in this cohort of apparently 
healthy subjects. In comparison to a study conducted in 
85 year olds [33], fewer subjects in our cohort had anaemia 
of chronic disease, anaemia of chronic kidney disease, or 
anaemia of multiple aetiologies.
C-reactive protein (CRP) and fibrinogen were posi-
tively associated with hepcidin under adjustment for age; 
all three proteins are induced by interleukin-6 (IL-6) [44]. 
However, the association of hepcidin with CRP lost signifi-
cance when adjusting for ferritin and for body mass index, 
possibly because ferritin is also an acute phase protein, or 
because low-grade inflammation was rare in this general 
community cohort. In contrast, the relationship of hepci-
din with fibrinogen remained significant under the same 
adjustment, and also under additional adjustment for 
CRP. This links hepcidin to fibrinogen and coagulation 
which has been first explored upon the observation that 
heparins can modify hepcidin expression in vitro and in 
vivo [45].
Interestingly, hepcidin was negatively associated with 
γ-GT levels under adjustment for ferritin but not without 
such adjustment, possibly due to down-regulation of 
hepcidin by alcohol [46]. Chronic sizeable alcohol con-
sumption, as was prevalent in study subjects, is expected 
to decrease hepcidin [46] and favour iron accumulation 
[47] while increasing γ-GT. Hepcidin levels in those with 
high alcohol intakes might therefore have been upregu-
lated through increased iron stores and down-regulated 
through ongoing alcohol consumption itself, resulting in a 
null association with γ-GT when not conditioning on iron 
stores.
Table 5: Associations of serum hepcidin concentration and derived variables with 10-year risk of cardiovascular disease. 
Variable    Tertile     All subjects    Women    Men
Hazard ratio 
(95% CI)
  p-Value  ptrend Hazard ratio 
(95% CI)
  p-Value  ptrend Hazard ratio 
(95% CI)
  p-Value  ptrend
  First   1.00 (Ref.)      1.00 (Ref.)      1.00 (Ref.)   
Hepcidin   Second  0.75 (0.45, 1.25)  0.270  0.623  0.52 (0.23, 1.21)  0.130  0.358  1.01 (0.49, 2.07)  0.983  0.911
  Third   1.00 (0.61, 1.65)  0.992    1.05 (0.52, 2.10)  0.899    1.00 (0.48, 2.07)  0.995 
Hepcidin-   First   1.00 (Ref.)      1.00 (Ref.)      1.00 (Ref.)   
Ferritin-   Second  0.73 (0.45, 1.18)  0.200  0.327  0.52 (0.24, 1.12)  0.096  0.357  0.90 (0.49, 1.68)  0.747  0.686
Ratio   Third   0.69 (0.40, 1.18)  0.178    0.58 (0.28, 1.22)  0.152    0.80 (0.37, 1.75)  0.583 
Hepcidin-   First   1.00 (Ref.)      1.00 (Ref.)      1.00 (Ref.)   
TFS-   Second  0.63 (0.37, 1.07)  0.085  0.689  0.56 (0.26, 1.23)  0.150  0.410  0.73 (0.35, 1.52)  0.398  0.948
Ratio   Third   0.95 (0.58, 1.56)  0.844    0.77 (0.37, 1.57)  0.470    1.11 (0.55, 2.25)  0.767 
CI, confidence interval; Ref., reference group; TFS, transferrin saturation. There occurred 91 incident CVD events in 675 subjects. Corre-
sponding numbers by sex are 50 events in 325 men, and 41 events in 350 women. Analyses were adjusted for age, sex, C-reactive protein, 
anaemia, and the Framingham risk score variables diabetes mellitus, current smoking, systolic blood pressure, and total and high-density 
lipoprotein cholesterol.
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Similar considerations may explain the significant sex 
differences in the relationship between average long-term 
alcohol consumption and hepcidin levels. In men, this 
relationship was consistent with hepcidin reflecting iron 
retention, as is plausible given their substantial alcohol 
intakes. Women consumed much less alcohol such that 
the direct effect of alcohol on hepcidin expression may 
have had relatively greater weight.
Dietary haeme but not non-haeme iron intake was 
positively associated with hepcidin only in women. This is 
coherent given that iron absorption adapts to iron require-
ments in healthy individuals, women in our sample had 
lower iron stores than did men, and haeme iron is more 
efficiently absorbed than non-haeme iron [1, 2, 43].
Table 4 shows the selected independent predictors 
of hepcidin serum concentration. It reinforces the over-
whelming dependence of hepcidin on ferritin levels, and 
shows that conditional on its most important other modu-
lators, hepcidin levels decline with age and are depend-
ent on circulating iron levels which are lower with more 
advanced age [1]. This also confirms experimental data 
that iron availability dominates inflammation in regulat-
ing hepcidin expression [1, 48].
We found no significant associations of hepcidin, of 
hepcidin-to-ferritin ratio, or of hepcidin-to-transferrin 
saturation ratio with carotid atherosclerosis or with CVD 
(Online Table 1 and Table 5). This contrasts to the results 
of a recent report which linked increased hepcidin or 
hepcidin-to-ferritin ratio to the presence of carotid plaque 
in healthy postmenopausal women [17]. Differences in 
study design may account for this discrepancy: Galesloot 
and colleagues [17] correlated hepcidin measurements to 
the presence of plaque 3–5 years later, while we assessed 
hepcidin and atherosclerosis at the same time point. 
Their sample may have been subject to more pronounced 
selection effects, as of 22,451 subjects initially randomly 
selected, only 766 were included, while in this study, of 
702 subjects participating in 2000, 694 were included. 
Importantly, hepcidin levels were substantially higher 
in their study, and the levels they found associated with 
excess plaque occurred in only 2% of our female partici-
pants, leaving the possibility that only very high hepcidin 
levels are related to plaque. In that case it will be interest-
ing to identify the source of such high levels.
Our results are in line with previous findings in Apoe-/- 
mice that hepatic hepcidin expression was unaffected by the 
progression of atherosclerosis [14], and that atherosclerotic 
plaque size was not increased with elevated macrophage 
iron [14], findings that question the notion that hepcidin 
exerts proatherogenic effects by promoting macrophage 
iron retention [10].
There are other epidemiologic studies reporting posi-
tive associations of hepcidin with vascular endpoints, 
including arterial stiffness [19] and cardiovascular events 
[18] in patients on maintenance haemodialysis. These 
findings in diseased subjects are of interest but may not 
necessarily apply to healthy subjects.
Strengths of our study include that its participants 
are well characterised and near-ideally representative 
for the general population, that blood was sampled at 
uniform time points and in the absence of acute infection 
in all subjects, ruling out major influences of inflamma-
tion [1] and of diurnal variations [36] on hepcidin levels. 
As this is a population-based study investigating a rep-
resentative random sample of healthy adults, significant 
selection bias was unlikely. Among its weaknesses is 
that, while a sufficient number of subjects with athero-
sclerosis were included, there were relatively few subjects 
that experienced CVD events in each sex group, and that 
we had no data on insulin resistance, which may be an 
important determinant of hepcidin concentrations [49]. 
Another potential weakness is that we abstained from 
correcting for multiple testing; we performed many at 
times highly correlated tests, and in this setting correct-
ing for multiplicity while maintaining acceptable power 
is challenging.
In summary, in this study involving elderly subjects 
from a general population, γ-GT and fibrinogen were the 
most significant independent correlates of hepcidin only 
surpassed by ferritin, and hepcidin was not associated 
with prevalent carotid atherosclerosis or with incident 
cardiovascular disease.
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